Occudo Quantitative Strategies’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

Occudo Quantitative Strategies’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-33,808	Closed	-$45K	–	1466
2022 Q1	$45K	Sell	33,808 -29	-0.1%	-$47	﹤0.01%	1082
2021 Q4	$88K	Buy	33,837 +4,389	+15%	+$13.3K	0.01%	968
2021 Q3	$92K	Buy	29,448 +14,533	+97%	+$48.5K	0.01%	927
2021 Q2	$55K	Buy	+14,915	New	+$49.6K	0.01%	837

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCM

MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Occudo Quantitative Strategies's PHAS Position: Q2 2022 in Review

Occudo Quantitative Strategies sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q2 2022, closing a stake of 33,808 shares — an estimated $45K sold.

Occudo Quantitative Strategies first reported a position in PHAS in Q2 2021 and held it in 4 quarters. The position peaked at $92K in Q3 2021. 49 funds tracked by Wall St. Rank hold PHAS as of Q2 2022.

Occudo Quantitative Strategies reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Occudo Quantitative Strategies sold 33,808 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $45K.
Occudo Quantitative Strategies first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
Occudo Quantitative Strategies's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $92K in Q3 2021.
49 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2022, filed 15 Aug 2022.